Cash/Burn From SEC Filing For Period: 

Q1'20

GTHX

G1 Therapeutics

G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer.

Cash

$242.2M

Burn Rate

-$31M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Trilaciclib

Metastatic Colorectal Cancer

Phase 3 TBA

TBA

Trilaciclib

Breast Cancer ( I-SPY 2)

Phase 2

TBD

Rintodestrant (mono)

ER+, HER2- BC

Phase 1/2a (Safety Data)

Q4 2020

Lerociclib (+ Tagrisso)

NSCLC

Phase 1/2

TBD

Lerociclib (+ fulvestrant)

ER+, HER2- BC

Phase 1/2 (Safety & Efficacy Data)

Q3 2020

Rintodestrant (+ palbociclib)

ER+, HER2- BC

Phase 1a TBD

TBD

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon